Figure 5 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies

<p>Identification of candidate compounds selectively targeting tB-TNBC cells. <b>A,</b> Heatmap showing the transcriptomic expression of tB-markers in a panel of breast cancer cell lines. <b>B,</b> Schematic representation of the FDA-approved drug library screening workflow. Cell viability heatmap shows the response of each cell line to the 3,200 tested compounds. ***, <i>P</i> < 0.001. <b>C,</b> Dot plot of average cell viability (%) in tB-TNBC (<i>x</i>-axis) and nB-TNBC (<i>y</i>-axis) cell lines after treatment. Dotted red and blue lines indicate the viability thresholds used for compound selection (<20% viability in tB-TNBC and >20% in nB-TNBC). Colored dots highlight the selective compounds. <b>D,</b> Heatmap showing the viability percentages of the selected compounds across the four TNBC cell lines used in the screen. <b>E,</b> Correlation plots showing the association between <i>ACTA2</i>, <i>TAGLN</i>, and <i>TPM2</i> expression (log<sub>2</sub> TPM + 1) and dasatinib sensitivity (AUC) in breast cancer cell lines. Red lines, regression fit; shaded areas show 95% confidence intervals. <i>P</i> values calculated by Pearson correlation. <b>B,</b> Created in BioRender. Rodilla, V. (2026) <a href="https://BioRender.com/qpb7bux" target="_blank">https://BioRender.com/qpb7bux</a>.</p>